Nail dystrophy
Methodology & AI Transparency ⓘ
Nail dystrophy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Nail dystrophy (L60.3; Hair Loss, Alopecia & Scalp Conditions) utilize hair-pull test [Nail dystrophy L60.3] and objective Serum Ferritin [Nail dystrophy L60.3] targets (70 – 150 ng/mL (L60.3)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code L60.3 categorizes Nail dystrophy under Hair Loss, Alopecia & Scalp Conditions.
- 3 Typical cash cost range: Primary evaluation for Nail dystrophy incorporates hair-pull test [Nail dystrophy L60.3] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Nail dystrophy: maintaining Serum Ferritin [Nail dystrophy L60.3] within 70 – 150 ng/mL (L60.3).
Ask our AI Specialists anything about Nail dystrophy
What Is Nail dystrophy?
Physicians managing Nail dystrophy (L60.3; Hair Loss, Alopecia & Scalp Conditions) utilize hair-pull test [Nail dystrophy L60.3] and objective Serum Ferritin [Nail dystrophy L60.3] targets (70 – 150 ng/mL (L60.3)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Nail dystrophy (code L60.3) is or stress/nutrient-triggered telogen in Nail dystrophy (L60.3: shift), which Hair Loss, Alopecia & Scalp Conditions clinicians address while surveilling Serum Ferritin [Nail dystrophy L60.3] (70 – 150 ng/mL (L60.3)).
Common Symptoms & Clinical Signs
- • Presentation of Nail dystrophy (L60.3): gradual widening of in Nail dystrophy (L60.3: the central scalp)
- • Secondary Nail dystrophy clinical sign: excess telogen hair in Nail dystrophy (L60.3: shedding)
- • Symptom flares in Nail dystrophy correlating with Serum Ferritin [Nail dystrophy L60.3] deviation outside 70 – 150 ng/mL (L60.3)
- • Functional hair & scalp impact requiring hair-pull test [Nail dystrophy L60.3] evaluation (L60.3)
Nail dystrophy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L60.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Ferritin [Nail dystrophy L60.3] | 70 – 150 ng/mL (L60.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Nail dystrophy (L60.3: T4) | TSH 0.8 – 2.5 mIU/L (L60.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Nail dystrophy (L60.3: & Zinc) | 25(OH)D 45 – 70 ng/mL (L60.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Nail dystrophy
Treatment selection for Nail dystrophy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nail dystrophy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic hair Of 34 clinical trials, none had adequate safety reporting, 19 were partially adequate, 12 were inadequate, and 3 reported no side effects. JAMA dermatology • 2015-06-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 25830296 ↗ |
| New Insights on Photobiomodulation for the treatment of androgenetic hair: What a 795-Participant Study Found Using hair density (hairs/cm 2 ) as a measure of efficacy, the standardized mean difference (SMD) was 1.02 (95% CI: 0.68, 1.36) in favor of treatment over control (15 studies, pooled N = 795, p p = .08). The Journal of dermatological treatment • 2021-09-15 • Meta-Analysis | N = 795 | 91/100 | PMID 31746251 ↗ |
| Can This Approach Help? Inside the Latest Research on Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2·5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile. The British journal of dermatology • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32479641 ↗ |
| Can This Approach Help? Inside the Latest Research on Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms Secukinumab provided sustained improvements in nail disease, signs and symptoms of PsA, and a low rate of radiographic progression through 2 years in patients with concomitant nail psoriasis. Clinical and experimental rheumatology • 2022-05-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34494957 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of carboxytherapy in hair Carboxytherapy seems to be a promising therapeutic option for patchy AA and could be helpful as an add-on treatment of AGA but more than 6 sessions are required and adjuvants are recommended for maintenance of the results. Journal of cosmetic dermatology • 2018-12-15 • Randomized Controlled Trial | N = 80 | 88/100 | PMID 29460509 ↗ |
Nail dystrophy Patient Community & “People Like Me” Threads
Filter Nail dystrophy community threads and patient logs by age, biological sex, dosage, and treatment duration.